Teplizumab, or Tzield, is what’s called an immunomodulatory drug. This means that it disrupts the autoimmune process in the body, particularly the process of the body destroying its own beta cells. It can be administered to someone who is already showing signs of developing type 1 diabetes, specifically when they are in what’s known as “stage two.” When you are positive for two or more autoantibodies, have some blood sugars that are out of what’s considered normal, but don’t need insulin yet, you are in stage two. Read more.